News headlines about Amedica (NASDAQ:AMDA) have trended positive this week, according to Alpha One Sentiment. The research group, a subsidiary of Accern, identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amedica earned a news sentiment score of 0.44 on Alpha One’s scale. Alpha One also assigned news headlines about the medical equipment provider an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the company’s share price in the next few days.

Amedica (NASDAQ:AMDA) traded up 0.2466% during mid-day trading on Friday, reaching $0.3658. 46,426 shares of the company’s stock were exchanged. The firm’s market cap is $9.66 million. Amedica has a 12 month low of $0.35 and a 12 month high of $1.62. The stock has a 50-day moving average of $0.38 and a 200-day moving average of $0.51.

Separately, Maxim Group reissued a “buy” rating and issued a $5.00 price target on shares of Amedica in a report on Monday, April 24th.

WARNING: This article was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at

About Amedica

Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty.

5 Day Chart for NASDAQ:AMDA

Receive News & Stock Ratings for Amedica Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica Co. and related stocks with our FREE daily email newsletter.